2021 Revenues ($USD) : $265,166,000
2021 R&D spend : $41,329,000
2021 Number of Employees : 1,517
Fiscal Year End : 12/31/2020
Key People : Quentin Blackford, CEO; Douglas Devine, CFO; Mark Day, EVP, R&D; Judith Lenane, EVP, products and chief clinical officer; Daniel Wilson, EVP of strategy, corporate development and investor relations; Dietra Jones, EVP, clinical operations; Kaja Odegard, chief people officer; David Vort, EVP of sales; Allan Wilsker, EVP of information technology and customer service; Mazi Kiani, VP of quality and regulatory

About the company: Seeking to usurp the old-school Holter monitor as the standard of care in electrocardiograph monitoring and AFib detection, iRhythm develops the Zio XT platform with cloud-based data analytics and machine-learning capabilities for cardiac monitoring. Founded in 2008, the San Francisco-based company’s Zio service aims to offer quality clinical accuracy, positive patient experience and compliance. It also holds the promise of lower cost of care through the miniature, wearable patch that includes a breathable, waterproof outer layer and a strong adhesive with a flexible design for secure attachment on the left side of the chest. The company is led by CEO Quentin Blackford, who took up the position earlier this year after previously serving as COO of Dexcom. –SW